SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

PRODUCT INFORMATION

BAY 57-1293-d_4

Item No. 9004311

Formal Name:	N-[5-(aminosulfonyl)-4-methyl-2-thiazolyl]-N-methyl-4-(2-pyridinyl-d_4)-benzeneacetamide
Synonym:	Pritelivir-d_4
MF:	$C_{18}H_{14}D_4N_4O_3S_2$
FW:	406.5
Chemical Purity:	≥95% (BAY 57-1293)
Deuterium Incorporation:	≥99% deuterated forms (d_1-d_4); ≤1% d_0
Supplied as:	A solid
Storage:	-20°C
Stability:	≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

BAY 57-1293-d_4 is intended for use as an internal standard for the quantification of BAY 57-1293 (Item No. 22129) by GC- or LC-MS. The accuracy of the sample weight in this vial is between 5% over and 2% under the amount shown on the vial. If better precision is required, the deuterated standard should be quantitated against a more precisely weighed unlabeled standard by constructing a standard curve of peak intensity ratios (deuterated *versus* unlabeled).

BAY 57-1293-d_4 is supplied as a solid. A stock solution may be made by dissolving the BAY 57-1293-d_4 in the solvent of choice, which should be purged with an inert gas. BAY 57-1293-d_4 is soluble in chloroform, methanol, and DMSO.

Description

BAY 57-1293 is an orally bioavailable helicase-primase inhibitor.[1] It inhibits the ATPase activity of herpes simplex virus (HSV) helicase-primase (IC_{50} = 30 nM). It inhibits HSV replication in Vero cells (IC_{50} = 20 nM for both HSV-1 and HSV-2) and is also active against porcine and bovine HSV strains (IC_{50}s = 5 and 0.12 µM, respectively). *In vivo*, oral administration of BAY 57-1293 is effective against HSV-1 and HSV-2 in a lethal challenge model (ED_{50} = 0.5 mg/kg in mice and rats) and in a zosteriform spread model, at a dose of 15 mg/kg, in mice and Lewis rats.[2,3] It is also effective in a guinea pig model of genital herpes and a mouse model of ocular herpes. BAY 57-1293 reduces levels of amyloid-beta (Aβ) and phosphorylated Tau in HSV-1 infected Vero cells.[3]

References

1. Kleymann, G., Fischer, R., Betz, U.A., *et al.* New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease. *Nat. Med.* **8(4)**, 392-398 (2002).
2. Betz, U.A., Fischer, R., Kleymann, G., *et al.* Potent in vivo antiviral activity of the herpes simplex virus primase-helicase inhibitor BAY 57-1293. *Antimicrob. Agents Chemother.* **46(6)**, 1766-1772 (2002).
3. Wozniak, M.A., Frost, A.L., and Itzhaki, R.F. The helicase-primase inhibitor BAY 57-1293 reduces the Alzheimer's disease-related molecules induced by herpes simplex virus type 1. *Antiviral Res.* **99(3)**, 401-404 (2013).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM